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Development of multicellular organisms requires the differential usage of
our genetic information to change one cell fate into another. This process
drives the appearance of different cell types that come together to form
specialized tissues sustaining a healthy organism. In the last decade, by
moving away from studying single genes toward a global view of gene
expression control, a revolution has taken place in our understanding of
how genes work together and how cells communicate to translate the infor-
mation encoded in the genome into a body plan. The development of
hematopoietic cells has long served as a paradigm of development in gen-
eral. In this review, we highlight how transcription factors and chromatin
components work together to shape the gene regulatory networks control-
ling gene expression in the hematopoietic system and to drive blood cell
differentiation. In addition, we outline how this process goes astray in
blood cancers. We also touch upon emerging concepts that place these pro-
cesses firmly into their associated subnuclear structures adding another
layer of the control of differential gene expression.
Introduction
Hematopoiesis is one of the best understood develop-
mental pathways [1,2] and has extensively been studied
in mice. The origin of blood cell development in the
embryo is the mesodermal germ layer in the mam-
malian embryo, and hematopoietic specification occurs
in two waves: The first wave takes place in the
extraembryonic blood islands of the yolk sac and gives
rise to primitive progenitor cells with mostly erythroid
and myeloid potential [3,4]; the second wave gives rise
to definitive hematopoietic stem cells (HSCs) and takes
place at the ventral part of the dorsal aorta in the
aorta–gonad–mesonephros (AGM) region of the
embryo [5]. Cells emerging during the second wave
migrate first to the fetal liver and later to the bone
marrow. Here, they are maintained in a specialized
niche and are largely quiescent, and if growing, either
self-renew or enter differentiation to sustain mature
blood cell production throughout lifetime. All HSCs
are born from a specialist endothelial cell layer, the
hemogenic endothelium (HE), which communicates
with the dorsal mesenchyme. In response to signals,
HE cells undergo a cellular shape transition, the
endothelial–hematopoietic transition (EHT), forming
intra-aortic clusters, which undergo several maturation
steps before floating off into the bloodstream. Blood
cell development therefore involves a carefully regu-
lated cascade of gene expression changes that are regu-
lated by molecular mechanisms linking genomic
responses to a multitude of signals coming from the
outside. It matters, where a cell has been and who it
has talked to. In turn, it matters whether a cell is
responsive to an outside signal, making development
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and differentiation an intricate, but highly robust bal-
ancing act that occurs in multiple cells at the same
time. This review will summarize seminal studies,
which uncovered the players involved in this balancing
act and highlight the notion that signaling-responsive
transcription regulation and chromatin dynamics are
at the heart of the mechanisms maintaining and chang-
ing cellular identity. We will also highlight that per-
turbing any of these mechanisms leads to a
disturbance of differentiation and, in some cases, to
the development of malignant cells that have opted
out of normal growth and differentiation control.
Transcription factors control blood
cell development and differentiation
Blood cell lineage-specific gene expression is under the
control of specific transcription factors. A large num-
ber of studies employing genetically modified mice
showed that the absence of lineage specifically
expressed factors leads to a perturbation of differentia-
tion or a complete absence of the respective lineage.
One of the first examples of a knockout removing an
important TF was that of the erythroid-specifically
expressed TF GATA1, which led to a complete
absence of erythroid (and megakaryocytic) differentia-
tion, while other lineages appeared to be unperturbed
[6]. The underlying molecular mechanism of differenti-
ation defects in the absence of a lineage-determining
TF is the deregulation of genes carrying binding sites
for this TF. Knockout experiments also highlighted
the fact that TFs act in a hierarchical fashion. The
elimination of earlier acting TFs such as TAL1 or
RUNX1 affects HSC formation and thus the develop-
ment of the entire hematopoietic system, whereas elim-
ination of others such as PU.1 largely affects the
myeloid and B-cell lineages. Recent studies using sin-
gle-cell RNA-sequencing approaches have visualized
the successive activation of specific developmental tra-
jectories by performing ‘nearest neighbor’ analyses,
which determine changes in the gene expression pat-
terns of single cells and order them according to the
direction of increased maturation. Such analyses high-
light the different branches of the hematopoietic sys-
tem and show that they deviate from each other
earlier than previously thought [7,8]. Performing such
studies with hematopoietic cells lacking a lineage-de-
termining factor clearly showed the absence of specific
branches in the trajectory [9]. Another hallmark of the
hierarchical action of TFs is the finding that they are
often only critically required at specific stages of devel-
opment even if still expressed at other stages. Exam-
ples for this notion are again RUNX1 and TAL1, and
the removal of their genes from the germ line strongly
blocks HSC development, but when removing it condi-
tionally after HSCs have formed, their maintenance is
not affected [10–12].
However, such a clear-cut result is not seen with all
TF knockouts and the reason for this behavior is the
fact that TFs operate within large interacting protein
assemblies as explained in further detail below. TFs
have a modular structure with different domains that
fulfill different functions and interact with different pro-
teins. Recent studies showed that crippling TFs by
removing individual domains can have unexpected
effects that shed light on their actual function in gene
regulation and point to an amazing robustness of pro-
tein complex formation driving gene expression. An
example is again the transcription factor TAL1. Dele-
tion of the whole factor abolishes HSC emergence com-
pletely, but deletion of the DNA-binding domain alone
has a much milder phenotype and factor binding can be
detected at a subset of genomic targets [13]. A different
result was observed after removing the DNA-binding
domain from the ubiquitously expressed TF SP1. This
mutation affects all developmental pathways, and a
germ-line mutation is an embryonic lethal [14]. How-
ever, in contrast to lineage-determining factors, remov-
ing it conditionally later in development had very little
effect [15]. The explanation for this finding came with
the analysis of the differentiation of mouse embryonic
stem cells into blood precursors in vitro, which showed
that the knockout still expressed a truncated protein
and that the effect of the mutation on gene expression
was cumulative. The full knockout of the Sp1 gene was
incompatible with differentiation and so was the full
deletion of the SP1 orthologue SP3 in a SP1 hypomor-
phic genetic background, indicating that the truncated
version of SP1 needed SP3 to function. During the dif-
ferentiation of cells expressing a truncated Sp1, bulk
gene expression patterns of purified cells became more
and more diverse. Single-cell RNA-Seq experiments and
the analysis of differentiation trajectories of such cells
showed why this was the case: Cells entered the correct
gene expression trajectory, but seemed to do this at dif-
ferent time points, forming transcriptionally diverse cell
populations. In essence, cells do not execute cell fate
decisions as a cohort, meaning that robustness of differ-
entiation was lost [15]. However, the system could only
tolerate a certain level of deregulation: Once past the
progenitor stage, differentiation crashed, and mutant
cells were unable to form terminally differentiated blood
cells [16]. A break-down of robustness of differentiation
can also be seen when another crucial level of control of
differentiation is disturbed: the expression of correct TF
levels. Many crucial TFs show haploinsufficiency
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phenotypes when one genetic copy is deleted or expres-
sion levels are reduced by the mutation of important cis-
regulatory elements, with the kinetics of development
being perturbed. This notion is true for GATA2 whose
downregulation by the mutation of an essential enhan-
cer [17] or by haploinsufficiency [18] causes various
hematopoietic defects and predisposes to leukemia. The
latter is also true for a cis-regulatory mutation of the
gene encoding PU.1, SPI1 [19]. Last, but not least,
RUNX1 needs to be expressed at carefully controlled
levels to drive hematopoietic differentiation and specifi-
cation [20,21].
Taken together, these studies show that the effects
of the crippling of an essential TF or its gene on gene
expression control have to be seen within the context
of development being a dynamic and highly robust
process. The system is composed of large interacting
protein assemblies and partly redundant components,
which compensate until they fall apart or are malfunc-
tioning, meaning that the defect occurs way before
phenotypic alterations can be seen. The current chal-
lenge is to identify the point when this occurs. This
notion will become important when trying to interpret
how mutant transcription factors set differentiating
cells on the path to cancer.
Transcription factors collaborate and
respond to signals
TFs come in families that bind to specific DNA-binding
motifs within cis-regulatory elements such as enhancers
and promoters, which are responsible for determining
how a gene is regulated and when and in which cell type
it is expressed. Each regulatory region contains multiple
TF-binding motifs, which often are highly conserved
depending on the nature of a gene and whether its func-
tion is conserved in evolution. A good example is the
‘Heptad’, a consortium of co-localizing transcription
factors such as GATA2, TAL1, RUNX1, and FLI1 and
the bridging factors LDB1/LMO2 that specify the cis-
regulatory elements of genes expressed in hematopoietic
stem and progenitor cells [22,23]. The spatial arrange-
ment of TF-binding sites is often not conserved [24], but
there are exceptions with TFs that directly interact on
DNA and whose binding is interdependent. Here, the
spacing of binding motifs can be very precise, as, for
example, seen with the pair AP-1/TEAD in the hemo-
genic endothelium [25], the pair RUNX1/ETS1 [26], or
the GATA/E-Box motifs within the heptad [27].
As exemplified by SP1, ubiquitously expressed TFs
cooperate with tissue-specific factors to set up differen-
tial gene expression patterns, and thus, the binding pat-
terns of TFs are highly specific for each cell type [28].
Importantly, binding patterns are highly dynamic and
can be maintained in self-renewing cells [29] or change
during development [30,31]. In this context, it is note-
worthy that transcription is not a uniform process but
occurs in bursts that are regulated by the burst fre-
quency, indicating that genes are in intricate contact
with their environment [32,33]. The cell receives signals
from various sources, which trigger developmental
changes and are integrated within the genome by the
action of inducible and signaling-responsive TFs. Many
of these factors can be activated in all cells and include
the AP-1 (JUN/FOS) factor families, which respond to
MAP kinase signaling [34], STATs responding to cyto-
kine receptor signaling [35], SMADs mediating TGF-b
signaling [36,37], TEAD/YAP mediating Hippo signal-
ing [38], or NFAT family members (linked to Ca++-sig-
naling) [39]. As a result of the activation of such factors,
enhancer elements can be activated de novo, or become
more active, driving increased levels of gene expression.
However, note that also noninducible TFs present can
be regulated in their activity by signaling-dependent
post-translational modifications such as phosphoryla-
tion with RUNX1 being a prominent example [40].
While we have a fairly good idea about what regulates
the activity of inducible transcription factors, we know
very little about how the different modes of signal trans-
mission interplay with each other across the genome.
This notion becomes important when different signals
are being integrated at the genome level by regulating
TF binding. For example, the abolition of AP-1 binding
during hematopoietic specification by using a dominant-
negative version of FOS led to a loss of binding of the
Hippo signaling-responsive factor TEAD at the com-
posite genomic sites described above [25]. Hippo signal-
ing is activated by the onset of blood flow, which creates
biomechanical forces stimulating Rho-GTPase signaling
[41]. During T-cell activation, MAP kinase and Ca++
signaling are integrated by a cooperation of AP-1 and
NFAT and at a specific subset of sites with composite-
binding motifs one factor cannot bind without the other
[42,43], thus ensuring that genes respond only when
both signals are present. These few examples show that
we are only now starting to obtain a glimpse of the prin-
ciples and staggering complexity of how the multitude
of signaling inputs that a cell encounters are integrated
within the genome and shape a genomic response.
TFs can both activate and repress
gene expression and form dynamic
gene regulatory networks
A large number of Zn++ finger TFs are bona fide
repressors with REST, a factor that is required to
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repress neuronal genes in other tissues, being a promi-
nent example [44]. Other factors can activate or repress
depending on the genomic context, which determines
whether they recruit co-activator or co-repressors (see
below) or interfere with the activity of lineage-deter-
mining TFs that set up alternate gene expression pat-
terns. Examples for the latter are the B-cell
commitment factors PAX5 and GATA2. PAX5 is
required to activate the expression of B-cell-specific
genes, but at the same time represses the expression of
myeloid genes [45,46] and thus finalizes commitment.
GATA2 activates multiple hematopoietic genes but is
required for the repression of cardiac genes [47]. PU.1
and GATA-1 form a similar antagonistic pair during
erythropoiesis [48,49]. A very interesting example of
how to turn an activator into a repressor during
dynamic gene activation is provided by Mylona et al.
[50], who showed that the type of response of the
serum-responsive TF ELK1 depends on the timing of
its post-translational modification. The protein con-
tains multiple ERK kinase-dependent phosphorylation
sites that are modified with different kinetics, fast,
intermediate, and slow. After the fast sites are modi-
fied, co-activators and mediator are recruited and
genes are activated, once the slower sites are modified,
co-repressors are recruited and gene expression is
switched off. Many other TFs contain multiple phos-
phorylation sites as well, making it highly likely that
such dynamic behavior of factors responding to signal-
ing is widespread and ensures that gene expression
does not overshoot.
An important feature of TF function is the fact that
they can bind to genes encoding other TFs and form
gene regulatory networks (GRNs), and this is also true
for blood cells [31,51,52]. In order to be able to con-
struct such a network, it is necessary to identify regu-
latory relationships between TFs and their target
genes. This aim can be achieved by inference, a strat-
egy by which the expression of individual putative reg-
ulators is perturbed followed by determining which
genes respond and whether they are upregulated or
repressed [53]. A more direct way is to identify the
actual TF-binding events using in vivo footprinting [54]
or chromatin immunoprecipitation (ChIP) assays and
then link binding sites to their associated genes. GRNs
consist of nodes (TFs or TF families) that are inter-
connected (edges), all of which bind to non-TF genes
that actually specify a cell type (Fig. 1). It is now clear
that highly interconnected nodes are important for the
maintenance of a specific cell type. Moreover, it mat-
ters how the network is structured and how the differ-
ent components are wired. Factors binding and
regulating their own and other TF-encoding genes can
form recursively wired circuits, thus carefully control-
ling their expression levels and binding patterns, and
are a hallmark of self-renewing hematopoietic stem
and progenitor cells [29]. However, when differentia-
tion is kicked off by a signal or by the upregulation of
expression of a specific TF, connections are altered,
meaning that TF-binding patterns are altered as well,
and factors move to different locations [31]. A striking
example of how the expression of one factor can drive
the rewiring of an entire GRN is provided by experi-
ments that expressed an inducible version of RUNX1
in mouse embryonic stem cells with a RUNX1 null
genetic background. Differentiation of such cells to
blood cells in vitro is blocked at the hemogenic
endothelium stage. Induction of RUNX1 allows the
differentiation of the hematopoietic progenitor stage
and, importantly, leads to a genome-wide relocation of
other factors, such as TAL1, LDB1, and FLI1 to dif-
ferent locations close to RUNX1-binding sites. Impor-
tantly, at least at the early stages of induction,
relocation was reversible. Rewiring and RUNX1-de-
pendent differentiation into blood progenitors require
the chromatin reader BRD4 with the final complex
recruiting mediator and CDk9 kinase to activate tran-
scription [30,55]. The analogy of GRNs with differen-
tially wired circuits and the availability of global
binding and gene expression data have attracted the
attention of computational biologists and mathemati-
cal modelers who strive to create models that could
predict the behavior of GRNs in response to perturba-
tion [56]. However, these efforts face formidable chal-
lenges, both experimentally and bioinformatically. For
example, due to the signaling responsiveness of many
TFs and their cofactors, their binding does not neces-
sarily mean that a gene is expressed. So far, these
models are therefore only capable of predicting simple
subaspects of gene expression control, such as whether
a gene is likely to be expressed or not [57]. Due to the
multiple parameters feeding into the system, predicting
gene expression patterns in a dynamic or even a devel-
opmental context is so far out of reach. However, such
methodology is essential, if we want to predict the
response of a GRN to changes in transcription factor
binding as a result of DNA sequence changes, changes
in the signaling environment, or in perturbation exper-
iments such as drug treatment.
Transcription factors interact with a
specific chromatin landscape
The most important feature of TFs is that they recog-
nize specific DNA sequences and therefore are able to
read the genetic code. However, within the eukaryotic
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nucleus they encounter a formidable obstacle to this
process in the form of chromatin. Here, DNA is
wrapped around nucleosomes, which are then pack-
aged into higher-order structures of differential com-
paction, depending on whether the genes within these
structures are active, potentially active, or stashed
away in heterochromatin. In order for the genetic code
to be accessed by TFs, chromatin needs to be remod-
eled and modified, which is achieved by different
mechanisms. One mechanism is the opening of chro-
matin by pioneer factors, which are capable of binding
to nucleosomal DNA and then cooperate with other
factors to nucleate a transcription factor complex [58].
Other TFs interact with nucleosomes in different ways
with most factors binding the nucleosomal linker
regions [59]. All binding modes have in common that
after a stable TF assembly is established, TFs recruit
chromatin remodelers such as SWI/SNF complexes
that use ATP to ‘peel’ DNA off the nucleosome and
free up sequences for further binding [60]. A variant of
the second mechanism is ‘assisted loading’ whereby an
inducible factor binds, recruits chromatin remodelers
that enable the binding of a second factor which can-
not normally bind, and then leaves again, leaving sta-
bly remodeled and TF-bound chromatin behind
[61,62]. During the assembly process, TF complexes
recruit further cofactors such as histone acetyltrans-
ferases (HATs) that facilitate transcription by modify-
ing the N-terminal tails of the surrounding
nucleosomes and stabilize an open chromatin structure
that is devoid of nucleosomes and exists as a nuclease
hypersensitive site [63]. Given the importance of chro-
matin remodelers and modifiers in gene activation, it
does not come as a surprise that these proteins are
essential components of the regulatory machinery driv-
ing hematopoiesis [64–66].
The establishment of stable TF complexes and mod-
ified chromatin is not the only mechanism that is
required to activate transcription. TF and cofactor
complexes at the different enhancers and the promoter
of a gene contact each other within nuclear space [67]
and form large protein–DNA complexes on cis-regula-
tory elements that contain all the factors necessary to
activate mRNA synthesis by RNA polymerase, and
form a regulatory unit or chromatin hub [68]. The
architecture of such units can be simple or complex—
depending on the complexity of gene regulation during
development and in different tissues [69,70]. The rea-
son for such complexity is that during development,
genes can be regulated by a relay of differentially/tis-
sue-specifically active cis elements. A good example for
this notion is the chicken lysozyme locus, which is
expressed in the oviduct or in macrophages and uses
different and shared tissue-specific elements and fac-
tors to drive different regulatory modes of gene expres-
sion [71]. Moreover, even genes that are expressed in
every cell, that is, ‘housekeeping genes’, are regulated
by a relay of different factors thus keeping chromatin
A C D
B
Fig. 1. Development involves the alterations of gene regulatory networks. (A). Inferring regulatory relationships between transcription factor
genes by perturbation of the expression of one factor and measuring the gene expression response of all genes. Note that such
experiments require multiple measurements to identify statistically significant correlations. (B) Identifying regulatory relationships by direct
binding experiments as described in Ref. [119]. This includes digital footprinting, which identifies factor families binding to the same motif
or identifying the precise factor by using chromatin immunoprecipitation assays. Identified binding sites are then annotated to their rightful
promoter using promoter capture HiC (chromosome conformation capture). Compared with gene expression analysis, this strategy allows to
identify the differential wiring of GRNs in different cell types as depicted in C and D. Genes bound by the different TFs or TF families are
depicted as rectangles with the color highlighting their expression level as indicated in the figure.
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open and ensuring their sustained activity [31]. The lat-
ter mechanism highlights several important concepts in
gene regulation: An active, transcriptionally permissive
chromatin structure has to be actively maintained. In
the absence of activators, an inactive chromatin struc-
ture is established by repressing factors such as DNA
methyltransferase and histone deacetylases, which
methylate DNA and remove the acetylation mark
from histones. Secondly, an active chromatin pattern
that is nuclease accessible and carries active histone
marks is cell-type specific. Finally, it is not the pro-
moters, but the nonpromoter elements that contain the
information of tissue-specific gene expression and mir-
rors tissue-specific gene expression patterns [72,73].
Each transcription cycle is regulated by the balance
of activating and repressing factors responding to out-
side signals [74]. A large number of genes maintain
their transcriptionally active structure throughout cell
division. However, during mitosis, TF complexes are
largely stripped off chromatin and the question arises
how they reform. It is now clear that the parent set of
modified histones are distributed to the two daughter
strands. Modification patterns are therefore retained
during mitosis and mark genes that are activated after
mitosis [75]. It is also clear that certain TFs, such as
FOXA1, are capable of binding to mitotic chromatin
and form the basis of re-assembled TF complexes cre-
ating an active chromatin structure once the nuclear
environment has been reformed [74,76]. This transcrip-
tional memory is often dependent on signaling pro-
cesses, as shown during the formation of T-cell
memory: Stable TF binding allowing rapid reactivation
of genes by a second stimulus is dependent on the con-
stant reinforcement of factor binding by cytokine sig-
naling, employing inducible TFs. The absence of
cytokine signaling leads to a loss of an active and tran-
scriptionally permissive chromatin structure [77]. A
similar transcriptional memory is also established in
macrophages after a first inflammatory stimulus [78].
In a developmental context, this interplay of inducible
and constitutive factors establishing an early memory
of a previously received signal, also referred to as
priming [79], plays a decisive role in changing or main-
taining cell identities, as exemplified by neuronal devel-
opment of C. elegans. The developmental timing of
regulation of the Lsy-6 miRNA locus is dictated by a
NOTCH responsive an early enhancer. Those neuronal
precursor cells receiving the signal upregulate the gene
earlier as compared to those who did not with a strong
impact on gene expression patterns. The result is a
functional left–right asymmetry in otherwise morpho-
logically symmetric neurons [80]. Developing blood
cells are embedded in a sea of signals that have a
profound impact on gene expression. One of the chal-
lenges in the next years will be to unravel the order of
events of how genes are activated in hematopoietic
development and how external signals such as soluble
factors, mechanical forces, and spatial context regulate
the ordered formation of HSCs, cells of the different
hematopoietic lineages, and hematopoietic tissues such
as the thymus and lymph nodes. Single-cell analyses of
chromatin changes and expression patterns in develop-
ing cells together with spatial information will be cru-
cial to answer these questions [9,81]. Such studies need
to be combined with studies of surface molecule map-
ping [82] and the analysis of intracellular signaling
processes using advanced imaging—a formidable task.
Gene regulatory processes take place
in different parts of the nucleus
Gene regulation cannot be viewed without taking into
account where it takes place—in the nucleus (Fig. 2).
In recent years, it has become clear that this organelle
displays a highly organized structure, with genes occu-
pying different compartments depending on their activ-
ity state, the nature of their neighbors, and whether
they are transiently or permanently silenced [83–85].
The latter distinction is important, because transcrip-
tion can be rapidly switched off with genes remaining
in a poised state ready for further activation of repres-
sion, which is mediated by polycomb-repressive com-
plexes (PRCs). PRC complexes come as two general
types, PRC1 and PRC2. PRC2 contains the EZH1/2
methyltransferase, which deposits methyl groups on
histone H3K27. H3K27me3 binds the PRC1 complex,
which then ubiquitinates histone H2A at target pro-
moters resulting in a block of transcriptional elonga-
tion by RNA polymerase II, with the nonelongating
form of RNA polymerase still being associated at
these sites [86,87]. PRC complexes at promoters inter-
act with each other in nuclear space and form a long-
range network of transcriptionally silent genes [88,89]
that can intermingle with active genes [90] to rapidly
switch from one state to another. In contrast, true
heterochromatic regions such as centromeres, telom-
eres, repeat elements, and genes that are stably silenced
display a highly compact chromatin structure, are not
bound by RNA PolII, and are associated with the
nuclear periphery and the nuclear lamina [91].
Another level of chromosomal organization of
higher eukaryotes, which is associated with differential
gene expression, are topologically associated domains
(TADs) [92,93]. TADs partition chromosomes into reg-
ulatory domains inhibiting interactions between neigh-
boring chromosomal regions. TADs are in average
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100–200 kb in size, and their borders are bound by the
CCCTC-binding factor (CTCF) [94]. TADs can con-
tain both active and inactive genes displaying active
and inactive chromatin features, whereby the cis-regu-
latory elements of active genes interact with each other
inside, but not outside the TAD boundaries, forming
distinct subcompartments. The presence of CTCF is
essential for forming the TAD structure, and the pres-
ence of the boundary is important for the insulation of
genes from neighboring TADs. However, while CTCF
depletion abolishes TAD boundaries and insulation,
the organization into active and inactive genes and
their interactions are largely unaffected [95], which is in
line with the observation that TAD structures are not
tissue-specific and gene expression patterns are pro-
grammed by transcriptional and epigenetic regulators.
The vast majority of all TF and cofactor interactions
within gene regulatory elements take place within the
TAD boundaries with both TFs and cofactors partici-
pating in mediating these contacts [96] bringing
together large regions of DNA that are highly tissue-
specific [97]. Such extruded DNA loops can be encir-
cled and thus stabilized by the structural maintenance
of chromosome (SMC) complex, which contains cohe-
sin and condensin and uses ATP to reel in DNA [98].
It is likely that once formed, such structures are
required for genes to be able to respond to outside sig-
nals with a burst of transcription without having to
build up the entire 3D structure from scratch.
In the last few years, another feature within the
nucleus has caught attention—that of nuclear speckles
or membrane-less organelles (MLOs). Such structures
can be formed by liquid–liquid phase separation
(LLPS), which in biological systems is essentially a
process that is based on an interaction of molecules
that excludes water [99]. The nucleus contains a multi-
tude of such structures [100]. The best known are
nuclear speckles, which are the sites of splicing, and
the nucleolus, which is the site of rRNA synthesis that
originates from multiple repeats of rDNA genes. RNA
itself is sufficient to nucleate the formation of a nucle-
olus, which is faithfully reformed after cell division
[101]. Transcriptionally inactive heterochromatin con-
taining the heterochromatin protein HP1 consists of
another nuclear compartment at the nuclear periphery,
which protects the genome from mechanical stress
[102]. Proteins, such as HP1, are capable to form con-
densates by themselves [103] and a tell-tale sign of
their ability to do so are domains of intrinsically disor-
dered regions that appear to be devoid of structure
but are essential for phase separation [104]. A large
number of TFs, including those important for
hematopoietic differentiation processes [105,106], con-
tain such regions and are able to form large assemblies
without having to be too selective and sprout-specific
domains for every possible interaction [107]. Under
physiological salt condition, unmodified chromatin
undergoes phase separation in vitro or when injected
Fig. 2. Gene expression is controlled by transcription factors, chromatin components, and signaling and takes place in specialized
compartments within the nucleus. Round shapes highlight different factor assemblies and regulatory components as well as their
interactions linked by arrows. Rounded rectangular shapes highlight intranuclear/intracellular compartments. TAD, topology-associated
domain.
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into the nucleus, and this feature is modified by his-
tone acetylation and protein binding [108]. A large
number of factors contribute to a specific speckle type
indicating that such structures play a global role in
organizing nuclear processes [109]. Transcription is no
exception. Microscopic analysis had shown many years
ago that RNA polymerase II is organized in foci
within the nucleus and appears to occur at fixed sites
called ‘transcription factories’ [110]. More recently, the
partition of transcriptional processes into separate
assemblies was revived with the advent of global chro-
matin immunoprecipitation assays that uncovered that
genes with complex regulatory regions (also termed
‘superenhancers’) form large, DNA-dependent molecu-
lar assemblies. It was suggested that these assemblies
are able to undergo phase transition, thus forming reg-
ulatory entities with their own rules [111,112]. More-
over, it was also suggested that RNA polymerase II
can shuttle between a transcription and a splicing com-
partment depending on its phosphorylation status
[113]. However, while it is clear that such protein–
DNA assemblies containing TFs and their cofactors
form condensates in vitro and speckles in vivo, there is
still some controversy whether DNA-dependent factor
assembly represents true LLPS in living cells [114,115].
Nevertheless, it is now clear that compartmentalization
is an essential part of regulatory processes within the
nucleus, which drives the behavior of proteins in terms
of their assembly kinetics and activity of enzymes. The
challenge in the next years will be to precisely define
the role of each compartment and which factors are
involved in deciding how genes choose where to go to
and are involved in driving compartmentalization.
The malignant state—differentiation
going sideways
It is now clear that all of the mechanisms described in
this review so far are important for normal develop-
ment. Decades of research using knockout mice have
shown that the machinery regulating differential gene
expression is highly robust with a high inbuilt level of
redundancy. However, they also showed that defects
do not always manifest themselves immediately but
can appear later in the life of an organism in the form
of cancer, which is exemplified by certain types of
blood cancers, occurring in families with inherited
mutations in TF genes [116] that predispose patients
to acute myeloid leukemia (AML). However, most
cancer-causing mutations occur as somatic mutations
in early hematopoietic precursor and stem cells. Recur-
rent mutations are seen in genes controlling gene regu-
lation and epigenetic processes impacting cell fate
decisions [117]. This involves genes encoding TFs (i.e.,
RUNX1 or C/EBPa), chromatin remodelers and modi-
fiers (i.e., CHD4, CBP), polycomb family members
(i.e., EZH2), DNA methyltransferases (i.e., DNMT3A)
but also demethylases such as TET1/2. Moreover, we
also find mutations in genes encoding signaling mole-
cules controlling gene expression driving growth such
as RAS, genes encoding architectural proteins such as
CTCF, and genes encoding splicing factors. AML is
mostly a disease of the elderly, with mutations in genes
encoding transcriptional and epigenetic regulators
occurring first, which are then followed by additional
mutations in growth-promoting genes [118,119]. Such
successive acquisition of mutations first generates pro-
genitor cells with slightly impaired differentiation
capacity, which manifests itself as clonal hematopoiesis
where the normally tightly regulated balance of differ-
entiation is disturbed. One particular progenitor clone
expands and contributes excessively to blood cell
development without causing any overt disease pheno-
type. However, the seed is then laid for secondary
mutations, which then lead to a complete impediment
of differentiation and excessive malignant growth. It is
now clear that different driver mutations have a differ-
ent impact on the differentiation trajectory and the
epigenetic landscape. As a result of a defect in an
important regulator of cell fate driving a normal devel-
opmental trajectory, malignant cells adopt new identi-
ties distinct from normal cells and differentiation goes
‘sideways’ [120,121] (Fig. 3). The question now arises,
what is the nature of these new cellular identities and
how are they maintained as compared to normal cells.
Normal cellular differentiation processes have been
shaped and perfected by evolution over millions of
years, whereas malignant cell differentiation is a pro-
duct of patient-specific clonal selection that occurs in a
much smaller time frame: Being ‘imperfect’, the ques-
tion arises of why are malignant cells so difficult to
eradicate?
The answer to this question lays in the robustness
and plasticity of the differentiation process, that is, life
itself. Similar to normal cells, malignant cells are main-
tained by distinct GRNs that drive common and AML
subtype-specific signaling and metabolic pathways. It
should be noted that while cancers come in different
forms and can arise from many tissues, the rewiring of
normal GRNs into one that sustains a malignant phe-
notype is a hallmark of all of them. In AML, each
mutation shapes the aberrant differentiation process in
a different way, and even different mutations in a sin-
gle TF-encoding gene such as RUNX1, which give rise
to different aberrant version of RUNX1, can lead to
completely different disease outcomes and cellular
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identities with distinct chromatin landscapes [122,123].
Moreover, the inducible expression of different
RUNX1 oncoproteins causes an immediate reprogram-
ming of their chromatin and TF-binding landscape,
which is specific for each aberrant protein [123,124].
These data suggest that once different epigenetic land-
scapes have been set up after the first oncogenic hit,
cells on their way to malignancy tweak their GRNs to
compensate for the weakness of one differentiation
process to activate another to maintain a stable state
that is compatible with growth. We find the aberrant
activation of genes encoding lineage-inappropriate
TFs, which then become essential part of the network
of abnormal but not normal cells [121,125,126]. We
also find compensatory mechanisms whereby the muta-
tion of one allele encoding a TF leads to shift in the
GRN so that it now is dependent on the function of
the wild-type allele [127]. Compensatory mechanisms
and rewiring of signaling pathways are also common
and tend to appear during therapy with the develop-
ment of different subclonal populations. Examples for
this phenomenon are the eradication of cells carrying a
mutant FLT3 growth factor receptor after FLT3 inhi-
bitor therapy and the appearance of RAS mutant cells
either from preleukemic cells carrying the original dri-
ver mutation or from mutated leukemic cell escaping
therapy [118,128]. A glimmer of hope comes from
studies that profiled the chromatin landscape and gene
expression of prospectively isolated subclonal
population pairs from different patients carrying dif-
ferent founder mutations. Each subclonal population
displayed a different chromatin accessibility pattern
indicating that the acquisition of additional genetic
changes led to the formation of different chromatin
landscapes [129]. However, when different subclonal
pairs from different patients were compared, the chro-
matin accessibility patterns of each pair still clustered
in a patient-specific way, demonstrating that epigenetic
landscapes cannot drift apart in a disorderly way, that
is, the cells have still much in common. Identifying the
nature of these commonalities together with the differ-
ences will be crucial for the identification of patient-
specific therapies.
Perspectives
In this review, we have only been able to show a
glimpse of the complexity of the gene regulatory mech-
anisms that are encoded in our genome and that drive
cell differentiation and we face significant challenges in
our understanding of the molecular basis of develop-
mental processes. We have deliberately left out the
RNA world, and we have not mentioned how protein–
protein interactions and metabolic processes impact on
genome function and many other regulatory processes,
many of which also play part in multiple pathologies.
For our understanding of cancer as described above, it
becomes clear that (a) each type of cancer has to be
Fig. 3. Different types of mutations shape the development of alternate gene regulatory networks (GRNs) and drive subclonal evolution in
acute myeloid leukemia. The figure depicts the alternate differentiation pathway of normal and aberrant blood cell development, starting
from normal hematopoietic stem cells, which are capable of forming all blood cell types (left panel). In AML (right panel), the first mutational
hit creates a cell that may still be capable of some level of differentiation, but differentiation is impaired due to the skewing of their GRNs.
The nature of this impediment is different depending on the type of mutation. Once a second hit occurs, the GRNs of these cells are
skewed further during clonal evolution, differentiation is further impaired, and proliferating AML cells develop a new identity with GRNs that
are distinct from that of normal cells.
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seen as a different entity with an entirely unique
underlying biology, (b) that we need to understand this
biology if we want to get away from therapeutic
approaches that target unregulated growth only
(chemotherapy) which in itself is genotoxic, and (c)
that we need to start thinking how we can reprogram
GRNs without touching normal cells. Note, that these
statements are valid for a number of pathological pro-
cesses. We need to directly target the gene regulatory
machinery in a disease-specific way, and we need to
block the compensatory escape routes that are used by
cancer cells, be it the rewiring of signaling pathways or
increasing genomic instability thus jumbling GRNs
and speeding up evolution. With the development of
drugs targeting TFs such as MYC [130], RUNX
[131,132]), chromatin regulators (BET [133,134], MLL
[135]), and repair mechanisms (ATMi [135–137],
PARPi [138]), we are starting to develop the right tool
box. However, what is clear is that neither our normal
environment nor pathological processes can be under-
stood without knowing the rules of gene regulation
and cellular biology and the players dictating these
rules. This review is a passionate appeal to keep study-
ing how life operates in all its amazing complexity.
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